BrightSpring stockholders to sell 14 million shares in secondary offering

Published 10/06/2025, 21:22
BrightSpring stockholders to sell 14 million shares in secondary offering

LOUISVILLE - BrightSpring Health Services, Inc. (NASDAQ: BTSG), a healthcare provider with a market capitalization of $4.16 billion and impressive year-to-date returns of 40%, announced Tuesday that certain stockholders plan to offer 14 million shares of common stock in an underwritten secondary offering. According to InvestingPro data, the company maintains a "GREAT" financial health score, suggesting strong operational fundamentals.

The selling stockholders include affiliates of Kohlberg Kravis Roberts & Co. L.P. (KKR) and members of BrightSpring’s management team. According to the press release statement, the KKR selling stockholder intends to grant underwriters a 30-day option to purchase up to an additional 2.1 million shares.

BrightSpring, a provider of home and community-based health services, will not sell any shares in the offering nor receive any proceeds from the transaction. All proceeds will go to the selling stockholders.

Goldman Sachs & Co. LLC and BofA Securities are serving as lead book-running managers for the offering, while KKR Capital Markets LLC is acting as lead managing agent.

The offering is being made through a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on June 10, which became automatically effective upon filing.

BrightSpring provides services for complex populations and has been publicly traded on the Nasdaq exchange since its initial public offering. The secondary offering represents existing shareholders reducing their positions in the company.

The company noted in its announcement that the offering will be made only through a prospectus supplement and accompanying prospectus available from the lead managers.

In other recent news, BrightSpring Health Services reported a 26% year-over-year increase in total revenue for Q1 2025, reaching $2.9 billion. Despite the robust revenue growth, the company’s earnings per share (EPS) of $0.19 fell slightly short of the forecasted $0.20. Pharmacy Solutions led the growth with a 28% increase in revenue, contributing significantly to the company’s performance. Mizuho Securities raised its price target for BrightSpring Health to $26, maintaining an Outperform rating, citing the company’s strong start to the year and updated guidance that exceeded expectations. Additionally, BrightSpring held its annual meeting of stockholders, confirming the election of two Class I directors and ratifying KPMG LLP as the independent accounting firm for the fiscal year. The company also announced plans to divest its Community Living business in the second half of 2025. Analysts from Mizuho expressed confidence in BrightSpring’s trajectory, attributing positive momentum to effective management and strategic positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.